Drug Trial Radar · NCT05413655
A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 8, 2022
Primary completion
Dec 31, 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- ExcelsiorIndustry
- Sponsor type
- Industry
- Collaborators
- Formosa Biomedical Technology Corp.
- First posted
- Jun 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.
Conditions
- Alzheimer Disease
Interventions
EX039Drug
The dosage form of EX039 is the capsule for oral use
PlaceboDrug
The dosage form of Placebo is the capsule for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Alzheimer's Disease Assessment Scale-cognitiveTime frame: Week 28
- Change in Clinical Dementia Rating-Sum of BoxesTime frame: Week 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.